Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the development, commercialization and marketing of prescription therapies addressing women’s health and related endocrine conditions. Headquartered in Mississauga, Ontario, with commercial operations in Princeton, New Jersey, the company leverages licensing and co-promotion agreements to bring novel hormone therapies to market.
The company’s commercial portfolio includes CombiPatch, a combined estradiol/testosterone transdermal system indicated for hormone replacement therapy in post-menopausal women, and IMVEXXY, a low-dose estradiol vaginal insert for the treatment of dyspareunia associated with menopausal vulvar and vaginal atrophy. Both products are marketed under license from Endoceutics, Inc., and are sold in the United States and Canada through Acerus’s dedicated sales teams and strategic partners.
Beyond its marketed products, Acerus maintains a clinical development pipeline aimed at unmet needs in women’s sexual health and men’s hypogonadism. Lead programs include an injectable testosterone therapy for female sexual dysfunction and a transdermal gel formulation targeting male testosterone deficiency. The company also explores new delivery technologies and formulations to enhance the safety and convenience of hormone therapies.
Acerus is led by President and Chief Executive Officer Jonathan G. Barrett, whose background in pharmaceutical strategy and business development supports the company’s growth initiatives. Through its North American footprint and collaborative agreements, Acerus seeks to expand patient access to specialized endocrine treatments.
AI Generated. May Contain Errors.
Free ASPCF Stock Alerts